Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
600
Trial Sponsor
Trial Collaborator
Clinical Trial Start Date
November 20, 2019
0Primary Completion Date
January 19, 2021
0Study Completion Date
January 19, 2021
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
Chikungunya0
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus Naïve Controls0
Last Updated
July 3, 2023
0Allocation Type
Non-Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
This is a Phase 2 parallel-group age- and gender-matched open label study in healthy adults 18-65 years of age to assess the safety and immunogenicity of an alum-adjuvanted chikungunya virus-like particle vaccine (PXVX0317) in prior recipients of other alphavirus vaccines versus alphavirus naïve controls.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
